Generated by AI
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.
Website4930 Directors Place
San Diego, CA, 92121
United States
The latest articles about KURA.
Analyst rates Kura Oncology a Sell: $5.85 fair value is below $7.43; about $72 million in quarterly burn could leave net cash negative by end-2028.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Analyst rates Kura Oncology a cautious Hold: $6.75 implies roughly 10% downside, balanced by 53% Q3 KOMZIFTI sales growth and combination potential.
Summary of Nov 17's posts. Generated by AI.
Investors talking about KURA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.